Dr. Srdan Verstovsek on JAK2 Inhibitors as a Treatment for Myelofibrosis
Srdan Verstovsek, MD, PhD, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, chief of the Section of Myeloproliferative Neoplasms, MD Anderson Cancer Center, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.
Verstovsek says the JAK2 inhibitor improves quality of life in patients and was approved based on data from a recent phase III trial. He adds that the JAK2 inhibitor is important for myelofibrosis because it is the only approved treatment currently available.
Verstovsek says upcoming JAK2 inhibitors, such as momelotinib and pacritinib, may be able to improve quality of life for patients as well. Both momelotinib and pacritinib are currently undergoing trials.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
